The government announced the expansion of vaccination against monkeypox on Friday July 8, after an opinion from the High Authority for Health (HAS) to this effect. Who is concerned ? We take stock.
While contaminations with monkeypox continue to increase with 721 cases confirmed in France on Friday by Public Health France, the High Authority for Health has decided to recommend “preventive vaccination” to the groups most exposed to monkeypox in a press release released this Friday, July 8.
François Braun, Minister of Health and Prevention, immediately announced that preventive vaccination will be offered to people at high risk of being infected with the monkeypox virus.
In accordance with the recommendations @HAS_healthpreventive vaccination will be offered to people at high risk of being infected with the virus. #monkeypox. We will organize ourselves so that it can be available, for those who wish, from the beginning of next week.
— Francois Braun (@FrcsBraun) July 8, 2022
Who is concerned ?
Are concerned “men who have sex with men and trans people who have multiple partners, people in a situation of prostitution, professionals working in places of sexual consumption“, specified the HAS.
At this stage, HAS does not recommend preventive vaccination of healthcare professionals taking care of the sick, considering that the usual hygiene measures and the wearing of personal protective equipment make “the risk of contamination very low in practice”. This vaccination can however be considered “on a case-by-case basis, depending on exposure, the existence of individual risk factors or at their request”, she added.
The new categories eligible for preventive vaccination “will be able to start booking appointments next week if they wish, “assured Jérôme Salomon, director general of health, during a press briefing.
Note: if the majority of the cases identified concern the aforementioned groups, “other vulnerable groups are also at risk”, also recalled a WHO spokesperson interviewed by BFM TV. The World Health Organization which must meet for a new emergency committee no later than the week of July 18.
Marketed under the name Imvanex in Europe, the vaccine used is a 3rd generation vaccine (non-replicating live vaccine, that is to say that does not replicate in the human body), authorized in Europe since 2013 and indicated against smallpox in adults, details Le Figaro.